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Abstract
Objective: The anticonvulsant hypothesis posits that ECT’s mechanism of action is 
related to enhancement of endogenous anticonvulsant brain mechanisms. Results of 
prior studies investigating the role of the inhibitory neurotransmitter gamma-amin-
obutyric acid (“GABA+”, GABA and coedited macromolecules) in the pathophysiology 
and treatment of depression remain inconclusive. The aim of our study was to inves-
tigate treatment-responsive changes of GABA+ in subjects with a depressive episode 
receiving electroconvulsive therapy (ECT).
Methods: In total, 41 depressed subjects (DEP) and 35 healthy controls (HC) were 
recruited at two independent sites in Norway and the USA. MEGA-PRESS was used 
for investigation of GABA+ in the anterior cingulate cortex. We assessed longitudi-
nal and cross-sectional differences between DEP and HC, as well as the relationship 
between GABA+ change and change in depression severity and number of ECTs. We 
also assessed longitudinal differences in cognitive performance and GABA+ levels.
Results: Depressive episode did not show a difference in GABA+ relative to HC 
(t71 =	−0.36,	p = .72) or in longitudinal analysis (t36 = 0.97, p = .34). Remitters and non-
remitters did not show longitudinal (t36 = 1.12, p = .27) or cross-sectional differences 
in GABA+. GABA+ levels were not related to changes in antidepressant response 
(t35 = 1.12, p = .27) or treatment number (t36 = 0.05, p = .96). An association between 
cognitive performance and GABA+ levels was found in DEP that completed cognitive 
effortful testing (t18 = 2.4, p = .03).
Conclusion: Our results failed to support GABA as a marker for depression and ab-
normal mood state and provide no support for the anticonvulsant hypothesis of ECT. 
ECT-induced change in GABA concentrations may be related to change in cognitive 
function.
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SIGNIFIC ANT OUTCOMES
1. Gamma-aminobutyric acid (GABA+) levels were not related to 
ECT antidepressant response.
2. Change of GABA+ was related to cognitive performance in sub-
jects who completed cognitive testing.
LIMITATIONS
1. As some of the subjects were using medication at the same 
time as they underwent ECT, an effect on GABA+ from these 
medications cannot be excluded.
2. Even though statistical analysis corrected for site, the sites used 
different types of anesthesia and different methods for calcula-
tion of ECT dosage, which could influence results.
3. The technologic limitations of magnetic resonance spectros-
copy in GABA+ measurement limit the ability to detect shifts of 
GABA+ from intracellular to extracellular spaces (synaptic cleft).
1  | INTRODUC TION
Electroconvulsive therapy (ECT) is efficacious for treatment-resist-
ant depression ( 2003). While the procedure has been in use for more 
than eight decades, the mechanism of action remains unknown. The 
anticonvulsant hypothesis of ECT provides a unique treatment-
specific theoretical framework for the antidepressant mechanism 
of action (Sackeim, 1999). This framework posits that the therapeu-
tic outcome is related to enhancement of endogenous anticonvul-
sant brain mechanisms. Data that support this hypothesis include 
the observation that seizure threshold increases in some patients 
as they progress through the ECT series (Coffey, Lucke, Weiner, 
Krystal, & Aque, 1995; Krystal, Coffey, Weiner, & Holsinger, 1998; 
Sackeim, 1999). In addition, changes are noted in EEG seizure met-
rics including seizure morphology (ictal power, delta coherence, and 
postictal suppression) (Coffey et al., 1995; Perera et al., 2004) and 
increased electroencephalographic slow-wave activity in the pre-
frontal cortex (Sackeim et al., 1996). Positron emission tomography 
has demonstrated decreased cerebral blood flow after ECT, which 
may be consistent with a hypometabolic state (Nobler et al., 1994). 
The hypometabolic state that occurs after ECT may be related to 
increased concentrations of gamma-Aminobutyric acid (GABA), 
the predominant inhibitory neurotransmitter (Sackeim, Decina, 
Prohovnik, Malitz, & Resor, 1983).
Proton-spectroscopy (1H-MRS) measures chemical metabo-
lites in the brain including glutamate and GABA. In standard 1H-
MRS of GABA, the signal also includes additional macromolecules; 
hence, the measurement is commonly denoted GABA+. Multiple 
investigations utilizing 1H-MRS in depressed subjects have found 
inconsistent results. Two studies comparing GABA levels in medi-
cation-free recovered depressed subjects with controls found low 
GABA concentrations in the occipital cortex, and the prefrontal 
(both dorsomedial/dorsal anterolateral and ventromedial prefron-
tal) and anterior cingulate cortex (ACC) (Bhagwagar et al., 2008; 
Hasler et al., 2007). Brennan et al. (2017) used 1H-MRS to scan 
subjects with major depressive disorder (MDD) treated with cit-
alopram. They found that greater increases in GABA+ in the pre-
genual anterior cingulate cortex from baseline to days 3 and 7 of 
citalopram treatment were significantly associated with clinical re-
sponse. These small, positive studies provide some evidence that 
low cortical GABA+ could be a marker of a trait vulnerability to 
a mood disorder and a neurochemical correlate of an abnormal 
mood state. However, a larger study by Godlewska et al. investi-
gated GABA+ in the occipital lobe using 1H-MRS in depressed sub-
jects treated with escitalopram and found no difference between 
subjects and healthy controls at baseline or changes in GABA+ 
during treatment (Godlewska, Near, & Cowen, 2015). Similarly, 
Hasler et al. (2005) examined GABA+ in the ventromedial prefron-
tal cortex and the dorsolateral/anterior medial prefrontal cortex 
and found no difference between subjects with MDD and healthy 
controls. Further complicating the picture is the significant het-
erogeneity in the depressed population. Price et al. used 1H-MRS 
and found decreased GABA+ in the occipital lobe in subjects with 
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treatment-resistant depression versus subjects with nontreat-
ment-resistant depression and healthy controls (Price et al., 2009), 
while Gabbay et al. found decreased GABA+ in the ACC in young 
subjects who were stratified based on the presence of anhedonia 
only in the anhedonic MDD subgroup (Gabbay et al., 2017).
There are only two prior pre-/post-ECT 1H-MRS investigations, 
which have also shown mixed results. In 2003, Sanacora et al. (2003) 
assessed GABA+ with 1H-MRS in depressed subjects treated with 
ECT. Eight subjects with a diagnosis of MDD and a two-week medi-
cation washout period received ECT. Pre-/post-ECT 1H-MRS found 
a significant change in the mean GABA+ concentration in the occip-
ital cortex, increasing from 0.85 mmol/kg brain tissue (SD = 0.34) to 
1.51 (SD = 0.48) as seven of the eight subjects showed an increase. 
There was a concomitant decrease in depression severity, although 
no significant correlation was found between clinical response and 
change in GABA+. In 2018, Knudson et al. assessed pre-/post-ECT 
changes in the occipital and prefrontal cortices (Knudsen, Near, 
Blicher, Videbech, & Blicher, 2019). The inclusion of the prefron-
tal cortex, which has a role in regulation of emotional processing, 
was more relevant to depression-related neurocircuitry (Kaiser, 
Andrews-Hanna, Wager, & Pizzagalli, 2015). Eleven subjects with 
unipolar and bipolar depression were enrolled, and medications 
were continued throughout the study. They found no changes of 
GABA+ in the PFC, mean 0.249 (±0.04) versus 0.251 (±0.04), and 
no difference in the OCC (data not reported). Both studies acknowl-
edged the limits of interpreting their results given the small sample 
sizes. In summary, 1H-MRS investigations in depressed subjects fo-
cused on detection of treatment-related changes of GABA+ have to 
date been inconclusive.
1.1 | Aims of the study
We measured GABA+ in the ACC during a longitudinal investigation 
of ECT at two independent sites investigated the hypotheses that (a) 
ECT will be associated with increased GABA+ in the anterior cingu-
late in depressed subjects receiving ECT; and (b) changes in GABA+ 
will be related to clinical efficacy. An exploratory aim of this inves-
tigation was the assessment of GABA+ related to ECT-mediated 
changes in effortful cognitive functioning.
2  | MATERIAL AND METHODS
This pre-/post-ECT imaging investigation study was performed at 
the University of New Mexico Hospital and Haukeland University 
Hospital. Approval was obtained from both the Regional Committee 
for Medical and Health Research Ethics in Norway and the University 
of New Mexico Human Research Protections Office. For both study 
sites, the treatment group included depressed subjects with a severe 
depressive episode (DEP) who met criteria for treatment with ECT 
and were maintained on their psychotropic medications during the 
ECT series (see Table 2). Age (years) and gender-matched healthy 
comparisons (HC) were concurrently recruited from the same geo-
graphic areas.
2.1 | Inclusion and exclusion criteria
The study protocol at Haukeland University Hospital (HUH) has 
been previously reported (Oltedal et al., 2015). Inclusion criteria 
consisted of the following: unipolar or bipolar depressive episode, 
Montgomery-Asberg Depression Rating Scale (MADRS) (Williams 
& Kobak, 2008) >25, clinical indication for ECT, and age >18 years. 
Exclusionary criteria included the following: ECT during the preced-
ing 12 months, pregnant, inability to give written informed consent, 
or contraindications to MRI. HC had no psychiatric or neurological 
diagnoses and no medication use, except contraceptives. Twenty-
one DEP (48% female, mean age 44, SD ± 16 years) and 15 HC (60% 
female, mean age 41, SD ± 17 years) were included for joint analysis 
of GABA+ levels. Scans were conducted at four to six-week time 
intervals for DEP (mean 38 days, range: 15–71 days) and HC (mean 
40 days, range: 29–57 days).
At the University of New Mexico Hospital (UNMH), inclusion 
criteria consisted of the following: unipolar depressive episode and 
age range between 50 and 80 years. Additional inclusion and exclu-
sionary criteria were identical to the Norway site. Twenty DEP (60% 
female, mean age 63, SD ± 10 years) and 20 HC (60% female, mean 
age 59, SD ± 6 years) were included for joint analysis of GABA+ lev-
els. Scans were conducted at four to six-week time intervals for DEP 
(42 days, range: 14–63 days) and HC (42 days, range: 28–53 days).
2.2 | Assessments
MADRS (HUH) and 17-item Hamilton Rating Scale for Depression 
(HDRS-17; UNMH) confirmed depression severity. For combined 
analysis, the HDRS-17 total score was converted to the MADRS 
total score (Heo, Murphy, & Meyers, 2007). Patients were classi-
fied as responders or remitters using the following criteria: ECT re-
sponse was defined as more than 50% reduction in baseline MADRS 
and remission was defined as more than 50% reduction in baseline 
MADRS	and	a	post-ECT	MADRS	total	score	≤	10.	Prescribed	drugs	
during treatment and the number of ECT sessions administered were 
recorded.
Several neuropsychological tests were performed at both 
study site, whereas the Trail Making Test (Trails) Parts A and B 
(Reitan, 1958) was performed at both sites. Trails Part A measures 
simple visual scanning/attention, processing speed, number se-
quencing, which require low cognitive effort. Trails Part B measures 
complex visual scanning/attention, letter and number sequencing, 
processing speed, and cognitive flexibility, requiring high cognitive 
effort (Bowie & Harvey, 2006; Tombaugh, 2004). Although the Trails 
manual tends to cap the time for Part B at 300 s, we followed a 
testing of limits paradigm and allowed the participants as much as 
needed to complete the test (Lindenberger & Baltes, 1995). The raw 
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scores (total time to test completion in seconds) were used for the 
analyses, and the change in scores between pre- and post-testing 
was calculated.
2.3 | ECT procedure and anesthesia
Thymatron System IV (Somatics LLC) was used at both sites. DEP 
were hyper-oxygenated directly before and during the initiation of 
anesthesia to optimize induction of seizures. ECT parameters (elec-
trode placement, amplitude, pulse width, frequency, duration, and 
total charge), anesthetics, and seizure duration were recorded for 
each treatment.
At HUH, DEP received right unilateral electrode placement 
(RUL) and 0.5 millisecond (ms) pulse width. Stimulus energy was 
determined by an age-based method: Patient's age in years × 5 ≅ 
stimulus charge in mC (Abrams, (1988)). Anesthetic medications 
included thiopental (induction) and succinylcholine (neuromuscu-
lar blockade).
At UNMH, DEP started with RUL and 0.3 ms pulse width and re-
ceived as needed bitemporal electrode placement (BT, 1.0 ms pulse 
width) in the context of RUL non-response (n = 8). Seizure thresh-
old was obtained during the first session with subsequent stimulus 
dosage at 6 × threshold for RUL and 2 × threshold for BT. Further 
adjustments to energy occurred as needed for inadequate seizure 
induction, defined as <25 s of electroencephalogram (EEG) seizure 
activity or poor seizure morphology. Anesthetic medications in-
cluded methohexital (induction) and succinylcholine (neuromuscular 
blockade).
2.4 | Structural and 1H-MRS data acquisition
At HUH, a 3 Tesla GE Discovery 750 scanner system (Milwaukee, 
WI) with a 32-channel head coil was used. For structural MRI acqui-
sition, a 3D T1 weighted fast spoiled gradient echo (FSPGR) acquisi-
tion included the following parameters: Echo time/repetition time 
(TE/TR) = 2.9/6.7 ms, inversion time (TI) = 600 ms, flip angle = 8°, 
field of view (FOV) = 25.6 cm, and matrix size 256 × 256, giving 
isotropic voxel size of 1 × 1 × 1 mm. The FSPGR acquisition was 
used as localizer for positioning of the spectroscopy voxel across 
the midline in the anterior cingulate (ACC), angled in the sagittal 
plane aligned to the foremost slope of the corpus callosum (CC). 
For spectroscopic acquisition, 1H-MRS single-voxel point resolved 
spectroscopy (MEGA-PRESS) (Mescher, Merkle, Kirsch, Garwood, & 
Gruetter, 1998; Mullins et al., 2014) included the following param-
eters: TE = 68 ms, TR = 1,500 ms, 384 averages in total, resulting 
in a total acquisition time of 10 min. The 1H-MRS voxel measured 
30 × 30 × 30 mm (27 ml).
At UNMH, a 3-Tesla Siemens TIM Trio scanner (Malvern, PA) 
with a 32-channel head coil acquired the imaging data. For struc-
tural MRI acquisition, a T1-weighted multi-echo magnetization-pre-
pared rapid acquisition with gradient echo (MPRAGE) included 
the following parameters: TR = 2.53 s; TE = 1.64, 3.5, 5.32, 7.22, 
9.08 ms; TI = 1.2 s; flip angle = 7°; number of excitations = 1; slice 
thickness = 1 mm; FOV = 256 mm; matrix 256 × 256; and voxel 
size = 1 × 1 × 1 mm. For spectroscopic acquisition, the ACC loca-
tion was similar to HUH and the acquisition parameters included 
the following: TE = 68 ms; TR = 2,140 ms; 256 averages in total, 
giving an acquisition time of 10 min. The 1H-MRS voxel measured 
40 × 26 × 20 (20.8 ml). Acquisition parameters included the follow-
ing for HUH: spectral width was 5,000 Hz, 4,096 datapoints, with 
the ON editing pulse placed at 1.83 ppm and the OFF editing pulse 
placed at 7.43 ppm using a 16 ms sinc-weighted Gaussian edit pulse. 
The water peak is assumed to be at 4.68 ppm. Acquisition parame-
ters included the following for UNMH: spectral width was 1,200 Hz, 
2,048	 datapoints, with	 the	 ON	 editing	 pulse	 placed	 at	 1.90	 ppm	
and	 the OFF	editing pulse	placed	at	7.5	ppm	using	a	22.7	ms sinc-
weighted	Gaussian	edit	pulse. The	water	peak	 is	assumed	to	be	at	
4.68 ppm. The differences between the edit-on and edit-off spectra 
determined GABA+ quantification.
2.5 | 1H-MRS data processing
1H-MRS processing of the UNMH and HUH data was completed 
through a common pipeline using Gannet (Edden, Puts, Harris, 
Barker, & Evans, 2014). This includes steps for combination of coil 
element data, time-domain frequency and phase correction, expo-
nential apodization, fast Fourier transform (FFT), pairwise rejection 
of data for which fitting parameters are >3 standard deviations from 
the mean and subtraction to generate the edited difference spec-
trum. Statistical Parametric Mapping 12 (SPM 12, https://www.fil.
ion.ucl.ac.uk/spm/) completed segmentation of T1 images into gray 
matter, white matter, and CSF using a unified segmentation approach 
(Ashburner & Friston, 2005). Gannet performed GABA+ quantifica-
tion including tissue-class correction for gray matter, white matter, 
and CSF derived from the 3D T1 data (Edden et al., 2014; Harris, 
Puts, & Edden, 2015). SNR and linewidth estimates (full width at 
half maximum, FWHM) for HUH ranged from 12.0–30.7 and 13.1–
29.5 Hz for GABA, 34,688–85,708 and 7.57–14.10 Hz for water, 
and 75.10–303.56 and 6.97–15.24 Hz for creatine. At UNMH, the 
corresponding ranges were 2.5–21.5 and 17.7–31.8 Hz for GABA, 
127.20–1112.6 and 7.51–18.43 Hz for water, and 9.26–40.79 and 
7.12–26.92 Hz for creatine. Preprocessed spectra and the corre-
sponding model fit were inspected visually to check for aberrant 
features, and outlier rejection applied to flag suspicious estimates 
as described by Edden et al. (2014). Two subjects were removed 
from HUH. Spectra and model fits, as well as voxel placement for 
both sites, are shown in Figure 1. The choice of reference metabo-
lite (creatine or water) has vendor and treatment-related considera-
tions. Siemens scanners over estimate water (Mikkelsen et al., 2019), 
but creatine (Cr) may change over the course of an ECT series (Njau 
et al., 2017). To balance vendor and treatment-related changes, we 
use water (GABA+) as the reference for longitudinal comparisons, 
and creatine (GABA+/Cr) for cross-sectional comparisons.
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2.6 | Statistical analysis
Statistical analysis was conducted using the R software version 3.4.0 
(R Core Team, 2017). The Shapiro–Wilk test was used to test for 
normal distribution of the data. Summary statistics of sample char-
acteristics were assessed using chi-squared, two-sample t tests, or 
nonparametric tests if data were not normally distributed. Results are 
reported as mean or median, ±SD or range, as specified in the text. 
The primary analyses focused on the combined data sets (HUH and 
UNMH, controlling for age, sex, and study site) with follow-up tests 
for site-specific data (controlling for age and sex). Repeated meas-
ures analysis of variance (RM-ANOVA) assessed group differences 
(DEP and HC), the main effect of time, and group × time interaction. 
In addition, general linear models were constructed to assess the 
following: cross-sectional differences in GABA+ between DEP and 
HC; longitudinal differences in GABA+ in DEP pre- and post-ECT, 
changes in GABA+ related to change in MADRS or treatment num-
ber, and changes in GABA+ related to change in cognitive function-
ing (Trails A and B performance in seconds). Longitudinal change in 
GABA+ levels was measured as percentage change. The significance 
level for all tests was p < .05 with no multiple comparison correction.
3  | RESULTS
3.1 | Clinical outcomes and demographics
The joint analysis included 41 DEP and 35 HC. DEP and HC were not 
statistically different from each other based on age or sex. DEP improved 
in depression severity during the ECT series with 25 DEP meeting 
remission criteria and 16 DEP not meeting remission criteria. Details are 
given in Tables 1 and 2 shows the sample characteristics per site.
Twenty-four subjects from both sites completed cognitive test-
ing pre- and post-ECT Trails A: median raw score in seconds before 
treatment = 35 (11–64), median raw score in seconds after treat-
ment = 38.5 (15–90), U = 133.5, p = .65; Trails B: median raw score 
in seconds before treatment = 95 (55–360), median raw score in 
seconds after treatment = 107 (51–360), U = 128, p = .97. Both 
Trails A and B performance were normally distributed with all data 
within ± 3 standard deviations (SD).
3.2 | Longitudinal differences in GABA+ between 
DEP and HC
RM-ANOVA revealed no significant effect of group (DEP, HC; 
F = 1.04, p = .31), time (F = 0.31, p = .58) or time × group interac-
tion (F = 0.46, p = .50). Results are shown in Figure 2. For HUH, the 
time x group interaction was significant (F = 4.76, p = .03) but the 
main effects of group (DEP, HC; F = 1.14, p = .29) and time were not 
significant (F = 0.47, p = .50). For UNMH, group (DEP, HC; F = 7.10, 
p = .01) was significant, but time (F = 0.18, p = .67) and time × group 
interaction were not significant (F = 1.98, p = .17).
3.3 | Cross-sectional data: GABA+/Cr and Pre-/
post-ECT DEP/HC contrasts
Linear models for the combined data did not reveal differences 
in GABA+/Cr levels between DEP and HC at pre-ECT (combined: 
F I G U R E  1   Upper panel (left HUH, 
right UNMH): The GABA-spectrum in 
blue, the model fit is shown in red, while 
the residual is shown underneath, in black. 
Lower panel: Voxel placement at HUH 
(left) and UNMH (right). Both voxels are 
placed over the midline in the ACC. The 
voxel at HUH measures 30 × 30 × 30 mm 
giving a volume of 27 ml. The voxel at 
UNMH measures 40 × 26 × 20 mm, giving 
a volume of 20.8 ml
2.833.23.43.63.844.2
ppm
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t71 =	−0.36,	p = .72; HUH: t32 =	−1.15,	p = .26; UNMH: t36 = 1.25, 
p = .22) or post-ECT (combined: t71 = 1.17, p = .25; HUH: t32 = 1.11, 
p = .27; UNMH: t36 = 0.73, p = .47). The results for both sites 
combined were similar when using water as reference metabolite 
(GABA+) for the pre- (t71 = 0.34, p = .74) and post-ECT contrasts 
(t71 = 0.91, p = .37).
3.4 | Longitudinal analysis for DEP
Linear models did not reveal longitudinal changes in DEP GABA+ 
levels pre-/post-ECT (combined: t36 = 0.97, p = .34; HUH: t17 = 0.73, 
p = .47; or UNMH: t16 = 0.11, p = .91).
3.5 | Remitters/nonremitters
Linear models did not reveal a difference in percentage change of 
GABA+ in remitters versus nonremitters (combined: t36 = 1.12, 
p = .27; HUH: t17 = 0.29, p = .78; or UNMH: t16 =	−1.41,	p = .18). 
There were no cross-sectional differences between GABA+/Cr 
levels between remitters and nonremitters at baseline (combined: 
t36 =	−0.14,	p = .89; HUH: t17 =	−0.73,	p = .48; UNMH: t16 = 1.75, 
p = .10) or after treatment (combined: t36 =	 −1.16	p = .25; HUH: 
t17 =	−0.97,	p = .35; UNMH: t16 =	−0.39,	p = .70).
3.6 | Relationship between GABA+, MADRS, and 
number of ECT treatments
Linear models did not demonstrate a relationship between change 
in MADRS and GABA+ when corrected for number of ECT treat-
ments (combined: t35 = 1.12, p = .27; HUH: t16 = 1.92, p = .07; 
UNMH: t15 =	−0.75,	p = .47). Linear models did not demonstrate a 
relationship between number of treatments and GABA+ (combined: 
t36 = 0.05, p = .96; HUH: t17 = 0.64, p = .53; UNMH: t16 =	−0.59,	
p = .56).
3.7 | Relationship between GABA+ and 
neuropsychological testing
Linear models did not demonstrate a relationship between change 
in performance on Trails A (low cognitive effort) and percent-
age change GABA + levels (combined: t19 = 0.02, p = .98; HUH: 
t2 =	−1.46,	p = .28; UNMH: t14 = 0.57, p = .58). Linear models dem-
onstrated a relationship between change in performance on Trails 
B (high cognitive effort) and percentage change in GABA+ levels 
for both sites combined (β = 2.06, t18 = 2.4, p = .03) and UNMH 
(t14 = 2.67, p = .02), but HUH did not demonstrate this relationship 
(t1 =	 −6.20,	p = .10). In the Trails B data, two subjects were pos-
sible outliers (+2.56 SD and–2.88 SD of the mean). Removing these 
Variable DEP HC
t or X2 (p-value) for 
group differences
Number of subjects 41 35
Age in years, mean (SD) 53 (16) 53 (14) 0.40 (.67)
Sex female/male 22/19 22/13 0.33(.56)
Pre-ECT GABA+ level, mean 
(SD)
2.78 (0.37) 2.85 (0.58) 0.34 (.73)
Post-ECT GABA + level, 
mean (SD)
2.76 (0.31) 2.94 (0.73) 0.90 (.37)
Delta GABA + level, mean 
(SD)
−0.02	(0.47) 0.09 (0.83) −0.70	(.48)
Pre-ECT MADRS, mean (SD) 32.40 (5.96)
Post-ECT MADRS, mean (SD) 11.17 (9.01)
Delta MADRS, mean (SD) 21.23 (10.35)
Pre-ECT Trails A, median 
(range)
35 (11–64)
Post-ECT Trails A, median 
(range)
38.5 (15–90)
Delta Trails A, mean (SD) −1.38	(14.40)
Pre-ECT Trails B, median 
(range)
95 (55–360)
Post-ECT Trails B, median 
(range)
107 (51–360)
Delta Trails B, mean (SD) −1.04	(66.00)
Note: For data which were not normally distributed median (range) is reported. Time for Trails is 
reported in seconds.
TA B L E  1   Sample characteristics shown 
as means (SD) for DEP versus HC
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Variable HUH UNMH
t or χ2 (p-value) for site 
differences
Number of DEP/HC 21/15 20/20
Age in years, mean (SD) DEP/HC 44(19)/41(17) 63(10)/59(6) −4.63(<.001)/−3.58(.002)
Sex: female DEP/HC 10/9 12/12 0.78	(.43)/−0.29	(.77)
HDRS pre-ECT, mean (SD) DEPa  32.6 (7.6)
Change HDRS, mean (SD) DEP 21.1 (14.0)
MADRS score pre-ECT, mean 
(SD)
34.7 (5.1) 30.0(5.9) 1.67 (.10)
Change in MADRS, mean (SD) 21.3(10.9) 21.2(10.0) 0.04 (.97)
Number of ECT treatments DEP, 
mean (range)
10.23 (3–18) 11.2 (6–18) −0.79	(.45)
Pre-ECT Trails A DEP, mean (SD) 33.85 (12.33) 38.72 (9.03) −1.21	(.24)
Post-ECT Trails A DEP, mean (SD) 38.33 (19.87) 42.33 (12.80) −0.62	(.54)
Pre-ECT Trails B DEP, mean (SD) 96.45 (27.82) 137.72 (94.24) −2.18	(.04)






Lithium DEP 4 0
Antipsychotic DEP 16 7
Benzodiazepines DEP 0 6
Subtype: melancholic 17/20
Subtype: psychotic 1 10
Note: Clinical and demographic characteristics of depressed subjects receiving ECT (DEP) and 
demographically matched healthy comparison subjects (HC) at Haukeland University Hospital 
(HUH) and University of New Mexico Hospital (UNMH).
aHDRS-24 raw scores from UNM site only. HDRS-17 (subscale from HDRS-24) was used for 
MADRS conversion equation. 
bAntidepressant medication includes the following: SSRI, SNRI, TCA, MAOi, Bupropion. 
TA B L E  2   Sample characteristics per 
site
F I G U R E  2   Left panel: Individual GABA levels for each DEP (black) and HC (gray) before and after ECT treatment. Right panel: Means of 
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subjects did impact the relationship between GABA+ and effortful 
cognitive performance (β = 1.2, t16 = 2.1, p = .06). The association 
between GABA+ levels and Trails B is illustrated in Figure 3, showing 
that increased change in effortful cognitive performance is associ-
ated with increased GABA+ levels after ECT.
4  | DISCUSSION
Prior results from MRS studies looking at GABA+ in depressed sub-
jects have been inconsistent. While several studies found reduced 
GABA+ in depressed subjects (Bhagwagar et al., 2007; Hasler 
et al., 2007; Sanacora et al., 2003) and positive change in GABA+ 
with medication treatment (Bhagwagar et al., 2004; Sanacora, 
Mason, Rothman, & Krystal, 2002), other studies contradict these 
findings (Godlewska et al., 2015; Hasler et al., 2005). We did not find 
a difference between GABA+ in DEP and HC, nor did we find a rela-
tionship between GABA+ and treatment response. Of the two 1H-
MRS studies looking at GABA+ in ECT, the positive study looking at 
occipital GABA+ pre- and post-ECT (n = 8) was later contradicted 
by a slightly larger study (n = 11). Many of the studies mentioned 
above have small sample sizes. Studies with low sample size are 
more likely to overestimate effect size and have low reproducibility 
of results (Button et al., 2013). Also, previous studies focused on the 
occipital cortex, which has only been peripherally implicated in de-
pression-related neurocircuitry, whereas our study focused on the 
ACC, a brain region more directly implicated in depression (Hamilton 
et al., 2012). Pretranslational models with depression and electro-
convulsive stimulations have also failed to demonstrate changes in 
hippocampal GABA+ (Biedermann et al., 2012). Our results argue 
against GABA+ in the brain being either a trait-related biomarker 
of depression or a state-related biomarker for a depressive episode.
A negative association between GABA+ and effortful cognitive 
performance as measured by the Trails B was found in subjects that 
completed cognitive testing. That is, from baseline to after treatment 
with ECT, as GABA+ increased, performance on Trails B worsened 
suggesting that increased GABA+ was associated with worsening of 
effortful cognitive functioning, such as, complex visual scanning, at-
tention, and cognitive flexibility. This finding is consistent with prior 
research in adults with multiple sclerosis that found an association 
between greater levels of GABA+ in the posterior cingulate cortex 
and poor performance on the Trail Making Test (Cao et al., 2018). 
Several studies have linked baseline GABA+ and cognitive perfor-
mance. Increased GABA+ in the frontal cortex was positively cor-
related with improved general cognitive performance as measured 
by the Montreal Cognitive Assessment (MoCA) (Porges et al., 2017), 
whereas decreased GABA+ in the dorsolateral prefrontal cortex 
(DLPFC) was associated with greater degradation of performance 
in trials with higher memory load as tested by a work memory par-
adigm created by the authors utilizing face cues (Yoon, Grandelis, 
& Maddock, 2016). Our results suggest that increased GABA+ spe-
cifically in the anterior cingulate was associated with worsening of 
effortful cognitive performance. GABA may be contextualized with 
other ECT-cognitive biomarkers from structural MRI to help eluci-
date the mechanism of ECT-mediated cognitive impairment (Laroy 
et al., 2019; Oostrom et al., 2018).
A strength of our investigation is the relatively large sample 
size, compared to prior studies. However, due to (a) the possibility 
of vendor-specific GABA+ concentrations (Mikkelsen et al., 2019) 
and (b) a longer editing pulse used at UNMH compared with HUH 
F I G U R E  3   Association between percentage change in GABA+ levels and change in time solving neuropsychological tests. Left 
panel: Change in Trails A results (s) versus change in GABA+ levels; linear models (correcting for age, sex, and site) showed no significant 
relationship (t19 = 0.02, p = .98). The Pearson correlation is given in the figure. Right panel: Change in Trails B results (s) versus change in 
GABA+ levels; linear models (correcting for age, sex and site) demonstrated a significant relationship (β = 2.06, t18 = 2.4, p = .03). In both 
panels, the blue line represents the slope for the linear model with 95% confidence interval in gray. The Pearson correlation is given in the 
figure





























































     |  9 of 11ERCHINGER Et al.
(causing narrower band width and a resulting different amount 
of macromolecules contributing to the GABA+ signal) as well as 
other site differences, we have reported results separated by 
site in addition to our combined analysis. Our study has several 
limitations. First, while GABAergic medications (e.g. benzodiaze-
pines) were avoided, subjects were continued on their psychotro-
pic medications with minimal change throughout the ECT course, 
which could have affected GABA+ in the brain. Second, while our 
two independent sites had similar outcomes, they included differ-
ent patient samples (age and diagnoses), anesthetics (methohexi-
tal at UNMH thiopental at HUH), and ECT stimulation parameters 
(pulse width, seizure titration vs. age-, and demographic-formulas). 
The site differences in ECT stimulation parameters, titration, and 
anesthetics also prohibited analyses focused on seizure duration 
to assess other aspects of the anticonvulsant hypothesis. Third, 
one of the technologic limitations of MRS is limited spatial res-
olution given the low concentrations of neurotransmitters when 
compared to water (Lee, Adany, & Choi, 2017). We can capture 
large volume changes in GABA+ using spectroscopy, but are un-
able to discern intravolume shifts of GABA+ (e.g., from intracel-
lular spaces like the synaptic vesicle to extracellular spaces like 
the synaptic cleft). Fourth, the association between the change 
in GABA+ and worsening cognitive performance is a new find-
ing, but cognitive testing was performed on a small subsample of 
patients at both sites and was limited to the Trail Making Test. 
This finding requires replication in studies with larger sample sizes 
with additional neuropsychological tests to assess the type and 
cognitive domain specificity of this relationship. For the method 
used in our analysis, effect sizes of ~15% should have been de-
tectable for baseline difference of depressed subjects and healthy 
controls with group sizes of 20, for cross-sectional data (Brix 
et al., 2017). Given the data of our study, a retrospective power 
analysis suggested that future studies would need n > 40 to have a 
power of 0.8 for detecting longitudinal GABA+ change in patients 
over ECT treatment.
Our results provide no support for changes in GABA+ as a 
mechanism of antidepressant action for ECT, but other lines of 
inquiry of the anticonvulsant hypothesis may warrant investiga-
tion. Although assessed cross-sectionally with depressed sub-
jects, ECT-mediated changes in GABA+ from plasma or cerebral 
spinal fluid have yet to be investigated (Gerner & Hare, 1981; 
Kasa et al., 1982; Lu et al., 2014; Petty, Kramer, Dunnam, & 
Rush, 1990; Roy, Dejong, & Ferraro, 1991). Quantitative EEG 
assessments beyond seizure duration may also provide insights 
into anticonvulsant mechanisms (Coffey et al., 1995; Perera 
et al., 2004). The anticonvulsant hypothesis could be specific 
for a subtype of depression, and a more homogenous sample 
(e.g., melancholic depression) may demonstrate treatment-re-
sponsive changes in GABA+. Alternatively, the focus on a single 
neurotransmitter or brain region may be insufficient to cap-
ture the complexity of the brain's adaptation to ECT. A pivot 
toward other theoretical frameworks such as neurotrophic (ECT 
promotes neurogenesis or synaptogenesis) or hyper-connec-
tivity (ECT modifies aberrant neural connectivity) to explain 
ECT’s mechanism of action for both clinical and neurocognitive 
outcomes may be warranted (Farzan, Boutros, Blumberger, & 
Daskalakis, 2014).
5  | CONCLUSION
Our results provide no support for the anticonvulsant hypothesis 
as a mechanism of action for clinical outcome after ECT. We found 
no significant change between pre- and post-ECT GABA+ in the 
anterior cingulate cortex relative to the demographically matched 
HC. Cross-sectional analyses (pre- and post-ECT) revealed no group 
differences in GABA+ between DEP and HC. Longitudinal analy-
sis with DEP revealed no differences in GABA+. Finally, changes in 
GABA+ were unrelated to change in depression severity or num-
ber of ECT sessions. In contrast, our analysis suggests a negative 
effect of increased GABA+ during treatment on effortful cognitive 
performance as assessed by Trails B, showing that worsening effort-
ful cognitive performance may be associated with increased GABA+ 
levels after ECT. Despite the insignificant findings with respect to 
depression outcomes, our research is important as it contributes to 
the limited evidence on this topic. Moreover, in contrast to previ-
ous studies, our study had a relatively large sample size (41 DEP) 
collected at two independent study sites with the same anatomic 
1H-MRS acquisition as well as neurocognitive tests (Trails Part A and 
Part B).
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